ERBB2 and neoplasm: (171) demonstrated that the combined use of Sivelestat and trastuzumab may be a therapeutic strategy for HER2-positive BC due to NE inhibition, which enables tumor growth via tumor growth factor-α (TGF-α), which in turn blocks HER2 down-regulation enabled by trastuzumab.